- Net income for Huadong Medicine was reported at 2.84 billion yuan, which fell short of the estimated 2.91 billion yuan.
- The company’s revenue was 40.62 billion yuan, lower than the projected 41.36 billion yuan.
- There are currently 26 buys and 2 holds on the company’s stock, with no sells reported.
A look at Huadong Medicine Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smartkarma’s Smart Scores reveal an optimistic long-term outlook for Huadong Medicine Co Ltd A, with strong indications of growth potential. The company scores well across key factors, with particularly high ratings in Growth and Resilience. Huadong Medicine Co Ltd A is positioned favorably for future expansion and has shown a solid ability to withstand market challenges. While its Momentum score is slightly lower, the overall outlook remains positive.
Summary: Huadong Medicine Co., Ltd. operates in the wholesale and retail sectors of medicines, pharmaceutical preparations, biological products, and medical instruments. Additionally, the company’s subsidiaries are involved in the manufacturing of antibiotic medicines and biochemical products, further diversifying its portfolio and enhancing its market presence.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
